Parkinson Hastalığı için Noninvaziv Beyin Stimülasyonu: Terapötik Uygulamalar ve Klinik Perspektifler.
Noninvasive Brain Stimulation for Parkinson's Disease: Therapeutic Applications and Clinical Perspectives.
DOI: 10.14802/jmd.26168PMID: 42421444
Noninvasive Brain Stimulation for Parkinson's Disease: Therapeutic Applications and Clinical Perspectives.
DOI: 10.14802/jmd.26168PMID: 42421444
Identification of PDE10A binding ligands as potential therapeutics for the Parkinson's disease through a computational approach.
DOI: 10.1038/s41598-026-54373-8PMID: 42426040
Continuous Intrajejunal Levodopa-Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series.
DOI: 10.1002/mdc3.70738PMID: 42427120
Development and Validation of a Customised Yoga Therapy Module for People Living with Early Parkinsonism.
DOI: 10.1177/09727531261461074PMID: 42436650
Ageing-driven gastrointestinal variability in Parkinson's disease: implications for oral levodopa pharmacokinetics and formulation design.
DOI: 10.1016/j.ejpb.2026.115179PMID: 42413884
Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response.
DOI: 10.1016/j.parkreldis.2026.108422PMID: 42430982
Integrated multi-omics analysis identifies key microglial subpopulations and therapeutic targets in Parkinson's disease.
DOI: 10.1016/j.parkreldis.2026.108418PMID: 42430983
Access to Parkinson's disease treatments in the Middle East: a multi-national survey of availability, affordability, and utilization patterns.
DOI: 10.1016/j.prdoa.2026.100482PMID: 42473572
Syntaxin-4 at the Crossroads of Synaptic Plasticity and Neurodegeneration: From Molecular Mechanisms to Biomarker and Therapeutic Potential.
DOI: 10.2174/0118715273465885260623094946PMID: 42458952
Association of serum homocysteine, folate, and vitamin B₁₂ levels with cognitive function in levodopa-naïve patients with Parkinson's disease and mild cognitive impairment.
DOI: 10.5603/pjnns.111977PMID: 42411114
Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.
DOI: 10.1007/s00277-026-07163-1PMID: 42412128
Sex-specific gut microbiota and metabolite signatures in Parkinson's disease: implications for personalized therapeutics.
DOI: 10.1007/s11011-026-01924-7PMID: 42412259
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.